| 1. |
- Brantnell, Anders, 1983-, et al.
(författare)
-
Testbed for Material and Additive Manufacturing : Needs Analysis and Benchmarking
- 2022
-
Rapport (övrigt vetenskapligt/konstnärligt)abstract
- The manufacturing industry is facing a radical transformation due to digitization of production, demands on sustainable production, and possibilities of additive manufacturing (AM). AM, an alternative to mechanical manufacturing, provides several benefits such as rapid prototyping and low environmental impact. AM offers an opportunity for companies to improve their competitive conditions and value offerings while contributing to sustainable development. However, AM also poses challenges for companies, especially for small- and medium-sized enterprises (SMEs) as these companies often lack the financial resources and expertise to use new manufacturing methods. Testbeds are one way to support companies and accelerate change towards AM. This report builds on previous investigations concerning testbeds and AM and explores the possibilities and conditions to establish a testbed with a focus on AM in the Uppsala Region. This report builds on site visits and interviews with ten existing testbeds and site visits and interviews with 14 companies. The testbeds were spread around the country, and the companies were centered on the Uppsala Region.The findings are divided into two clusters: companies and testbeds. Altogether, nine companies either manufactured AM components or AM powder. All 14 companies had experience using AM, which is a clear indication that all these companies are early adopters or potential early adopters of AM. The companies that did not use AM (non-adopters) considered AM to be a promising technology but believed that AM did not fit with their current operations. The non-adopters believed AM was best suited for R&D, where proof of concepts and prototypes are developed and explored, which implies low technical maturity. Most the companies saw AM as a possibility for their operations. Non-adopters perceived AM as a possible complement to traditional manufacturing. Several non-adopters noted that they would adopt AM if customers requested it. Many non-adopters had difficulties identifying a business case for AM. In total, seven of the 14 companies had no experience with testbeds. Many companies envisioned a physical facility placed preferably near Uppsala and considered that a testbed could be helpful with material development. Many of the companies preferred a pay per use price model for the testbed. Furthermore, many of the companies were not willing to invest in creation of a testbed, but they were interested in using a testbed if available.Of the ten testbeds investigated, six integrate AM in their operations. Irrespective of whether the testbeds used AM, the establishment of the testbeds can be seen as an incremental trial and error process, which takes time and often starts with common projects. The path to establishing a formal testbed varied across the testbeds, but all the testbeds were developed based on the needs of their stakeholders such as academia or industry. Most of the testbeds needed to secure financing. Many of the testbeds initially received public funding, and these funds were used to establish facilities and set up an organization. The main challenge lies in having long-term financing covering running costs of rent, maintenance, human resources, and continuous investments. In addition to pay per use fees, a base funding originating (e.g., from member organizations) is crucial for long-term survival. The testbeds had difficulties estimating capacity use of the facilities, but all concluded the use is not yet 100%, so there are possibilities to increase the use of the facilities. It is clear that the testbeds need to define the value of the testbeds from a user perspective. Many testbeds experience challenges attracting SMEs irrespective of whether they focus on AM.Based on the investigation, this report formulates one key recommendation: Create a joint testbed building on the existing AM competences and facilities in Uppsala by combining existing testbeds (AM@Ångström and U-PRINT) into one testbed.That is, it is not viable to establish a totally new physical testbed as this would require several years of development and high investment costs. There are three main opportunities concerning this recommendation: 1) added value for Uppsala University and external users; 2) new user groups, and 3) specialization on life sciences.
|
|
| 2. |
- Carlsson, Raul, et al.
(författare)
-
Testing metrics for measuring the circularity while metrics are being standardized - TRACE CERTAINTY TRAnsitioning to a Circular Economy via CERTificAtion in INdusTrY : PROJECT FINAL REPORT Reference Number 2020-04410
- 2022
-
Rapport (övrigt vetenskapligt/konstnärligt)abstract
- This report describes the results and the learnings of a project that had the aim to develop a protocol for measuring circularity for products. The project was centered around an assessment of the real-world example of a lubrication cleaning and recirculation system by SKF RecondOil. The process of assessment required that the team match circularity in principle (how circularity can be measured in theory) with circularity in practice (how circularity can be measured in a real system). In the process, the team identified different ways to measure circularity based on drafted circularity principles (from ongoing ISO work on circularity). In the end, these alternatives were to be practically verifiable and certifiable. Learnings are to be fed into ongoing work on developing international standards (ISO) for assessing circularity. In the progress of the work, a framework for understanding and measuring circularity for the system at hand was developed including: a heuristic (diagram) describing a system of interest and a list of chosen circular economy principles see Figure 3. It is thought that the heuristic and list of principles could be used to guide an entity in the process of first, creating their system model, and then, making sense of and applying principles.
|
|
| 3. |
- Carlsson, Raul, et al.
(författare)
-
TRACE CERTAINTY - TRAnsitioning to a Circular Economy via CERTificAtion in INdusTrY : Testing metrics for measuring the circularity while metrics are being standardized: PROJECT FINAL REPORT Reference Number 2020-04410
- 2022
-
Rapport (övrigt vetenskapligt/konstnärligt)abstract
- This report describes the results and the learnings of a project that had the aim to develop a protocol for measuring circularity for products. The project was centered around an assessment of the real-world example of a lubrication cleaning and recirculation system by SKF RecondOil. The process of assessment required that the team match circularity in principle (how circularity can be measured in theory) with circularity in practice (how circularity can be measured in a real system). In the process, the team identified different ways to measure circularity based on drafted circularity principles (from ongoing ISO work on circularity). In the end, these alternatives were to be practically verifiable and certifiable. Learnings are to be fed into ongoing work on developing international standards (ISO) for assessing circularity. In the progress of the work, a framework for understanding and measuring circularity for the system at hand was developed including: a heuristic (diagram) describing a system of interest and a list of chosen circular economy principles see Figure 3. It is thought that the heuristic and list of principles could be used to guide an entity in the process of first, creating their system model, and then, making sense of and applying principles.
|
|
| 4. |
- Eggers, Kai M., 1962-, et al.
(författare)
-
Clinical and prognostic implications of C-reactive protein levels in myocardial infarction with nonobstructive coronary arteries
- 2021
-
Ingår i: Clinical Cardiology. - : John Wiley & Sons. - 0160-9289 .- 1932-8737. ; 44:7, s. 1019-1027
-
Tidskriftsartikel (refereegranskat)abstract
- Background Myocardial infarction with nonobstructive coronary arteries (MINOCA) is a heterogeneous condition. Recent studies suggest that MINOCA patients may have a proinflammatory disposition. The role of inflammation in MINOCA may thus be distinct to myocardial infarction with significant coronary artery disease (MI-CAD). Hypothesis We hypothesized that inflammation reflected by C-reactive protein (CRP) levels might carry unique clinical information in MINOCA. Methods This retrospective registry-based cohort study (SWEDEHEART) included 9916 patients with MINOCA and 97 970 MI-CAD patients, used for comparisons. Multivariable-adjusted regressions were applied to investigate the associations of CRP levels with clinical variables, all-cause mortality and major cardiovascular events (MACE) during a median follow-up of up to 5.3 years. Results Median admission CRP levels in patients with MINOCA and MI-CAD were 5.0 (interquartile range 2.0-9.0) mg/dl and 5.0 (interquartile range 2.1-10.0 mg/dl), respectively. CRP levels in MINOCA exhibited independent associations with various cardiovascular risk factors, comorbidities and estimates of myocardial damage. The association of CRP with peripheral artery disease tended to be stronger compared to MI-CAD. The associations with female sex, renal dysfunction and myocardial damage were stronger in MI-CAD. CRP independently predicted all-cause mortality in MINOCA (hazard ratio 1.22 [95% confidence interval 1.17-1.26]), similar to MI-CAD (p interaction = 0.904). CRP also predicted MACE (hazard ratio 1.08 [95% confidence interval 1.04-1.12]) but this association was weaker compared to MI-CAD (p interaction<.001). Conclusions We found no evidence indicating the presence of a specific inflammatory pattern in acute MINOCA compared to MI-CAD. However, CRP levels were independently, albeit moderately associated with adverse outcome.
|
|
| 5. |
|
|
| 6. |
- Eggers, Kai M., 1962-, et al.
(författare)
-
Predicting outcome in acute myocardial infarction : an analysis investigating 175 circulating biomarkers
- 2021
-
Ingår i: European Heart Journal. - : Oxford University Press. - 2048-8726 .- 2048-8734. ; 10:7, s. 806-812
-
Tidskriftsartikel (refereegranskat)abstract
- Aims There is a paucity of studies comprehensively comparing the prognostic value of larger arrays of biomarkers indicative of different pathobiological axes in acute myocardial infarction (MI).Methods and results In this explorative investigation, we simultaneously analysed 175 circulating biomarkers reflecting different inflammatory traits, coagulation activity, endothelial dysfunction, atherogenesis, myocardial dysfunction and damage, apoptosis, kidney function, glucose-, and lipid metabolism. Measurements were performed in samples from 1099 MI patients (SWEDEHEART registry) applying two newer multimarker panels [Proximity Extension Assay (Olink Bioscience), Multiple Reaction Monitoring mass spectrometry]. The prognostic value of biomarkers regarding all-cause mortality, recurrent MI, and heart failure hospitalizations (median follow-up <= 6.6years) was studied using Lasso analysis, a penalized logistic regression model that considers all biomarkers simultaneously while minimizing the risk for spurious findings. Tumour necrosis factor-related apoptosis-inducing ligand receptor 2 (TRAIL-R2), ovarian cancer-related tumour marker CA 125 (CA-125), and fibroblast growth factor 23 (FGF-23) consistently predicted all-cause mortality in crude and age/sex-adjusted analyses. Growth-differentiation factor 15 (GDF-15) was strongly predictive in the crude model. TRAIL-R2 and B-type natriuretic peptide (BNP) consistently predicted heart failure hospitalizations. No biomarker predicted recurrent MI. The prognostic value of all biomarkers was abrogated following additional adjustment for clinical variables owing to our rigorous statistical approach.Conclusion Apart from biomarkers with established prognostic value (i.e. BNP and to some extent GDF-15), several 'novel' biomarkers (i.e. TRAIL-R2, CA-125, FGF-23) emerged as risk predictors in patients with MI. Our data warrant further investigation regarding the utility of these biomarkers for clinical decision-making in acute MI.
|
|
| 7. |
- Eggers, Kai M., 1962-, et al.
(författare)
-
Sex-differences in circulating biomarkers during acute myocardial infarction : An analysis from the SWEDEHEART registry
- 2021
-
Ingår i: PLoS ONE. - : Public Library of Science (PLoS). - 1932-6203. ; 16:4 April
-
Tidskriftsartikel (refereegranskat)abstract
- Background Sex-differences in the pathobiology of myocardial infarction are well established but incompletely understood. Improved knowledge on this topic may help clinicians to improve management of men and women with myocardial infarction. Methods In this registry-based cohort study (SWEDEHEART), we analyzed 175 circulating biomarkers reflecting various pathobiological axes in 856 men and 243 women admitted to Swedish coronary care units because of myocardial infarction. Two multimarker panels were applied (Proximity Extension Assay [Olink Bioscience], Multiple Reaction Monitoring mass spectrometry). Lasso analysis (penalized logistic regression), multiple testing-corrected Mann- Whitney tests and Cox regressions were used to assess sex-differences in the concentrations of these biomarkers and their implications on all-cause mortality and major adverse events (median follow-up up to 6.6 years). Results Biomarkers provided a very high discrimination between both sexes, when considered simultaneously (c-statistics 0.972). Compared to women, men had higher concentrations of six biomarkers with the most pronounced differences seen for those reflecting atherogenesis, myocardial necrosis and metabolism. Women had higher concentrations of 14 biomarkers with the most pronounced differences seen for those reflecting activation of the reninangiotensin- aldosterone axis, inflammation and for adipokines. There were no major variations between sexes in the associations of these biomarkers with outcome. Conclusions Severable sex-differences exist in the expression of biomarkers in patients with myocardial infarction. While these differences had no impact on outcome, our data suggest the presence of various sex-related pathways involved in the development of coronary atherosclerosis, the progression to plaque rupture and acute myocardial damage, with a greater heterogeneity in women.
|
|
| 8. |
- Fornstedt, Helena
(författare)
-
Innovation Resistance : Moving Beyond Dominant Framings
- 2021
-
Doktorsavhandling (övrigt vetenskapligt/konstnärligt)abstract
- Science, Technology and Innovation (STI) research has mainly had an outlook that frames innovation in a pro-innovation, pro-firm, manner. Connected to this perception of innovation is a view of human and non-human resistance as a temporary unwanted response that will eventually be overcome. Studies on innovation resistance avoiding the pro-firm and pro-innovation bias are rare, and the findings provide a fragmented understanding of innovation resistance. Moreover, despite focusing on challenging the lingering pro-innovation bias, Critical Innovation Studies have not yet explained why this bias, accompanied by a derogatory view on resistance, lingers in academic writings. Therefore, this study aims to shed light on central presuppositions and limitations of the scholarly knowledge production on innovation and innovation resistance. Specifically, it aims to empirically explore the manifestation of innovation resistance and the dynamics involved in its entanglement with innovation processes. This is achieved through reviews of extant literature combined with an actor-network analysis of interviews, public documents and news articles concerning three different innovation processes. Using an actor-network theory lens, the study finds that innovation resistance is a process between programmes that manifests when an innovation programme intercepts an Other programme. The process consists of layered movements of resistance that entangle the Other with the innovation actor. The movements are conceptualised as non-programmatic behaviour, distortion, estrangement/interessement and rejection. The process enables the Other actor's agency and restricts the innovation actor's agency. The resistance can prompt accommodation from the innovation actor, consequently shaping the innovation process. For the Other, innovation resistance can protect from the influence of an unwanted innovation process. It can also be how the excluded Other (re)gains influence over an innovation process by which it is affected. Moreover, the study finds that the scholarly knowledge production around innovation and its resistance has been conducted from within the mega programme of Industrial Capitalism, including Top Tier journals and the Innovation Studies tribe programmes. Consequently, they lock out Other actors (such as the more than human world, people of colour, women, workers and research non-programmatic with the Top Tier journals and the Innovation Studies programmes), making them essentially invisible or negligible in the innovation research. This explains the narrow system boundaries of the field (allowing researchers to assume that innovation processes lead to a positive sum-game) and the pejorative view on resistance.
|
|
| 9. |
- Hjort, Marcus, 1988-, et al.
(författare)
-
Biomarker Concentrations and Their Temporal Changes in Patients With Myocardial Infarction and Nonobstructive Compared With Obstructive Coronary Arteries : Results From the PLATO Trial
- 2023
-
Ingår i: Journal of the American Heart Association. - : American heart association. - 2047-9980 .- 2047-9980. ; 12:1
-
Tidskriftsartikel (refereegranskat)abstract
- Background: The pathobiology of myocardial infarction (MI) with nonobstructive coronary arteries (MINOCA) is often uncertain. Investigating biomarker concentrations and their changes may offer novel pathophysiological insights.Methods and Results: In this post hoc study of the PLATO (Platelet Inhibition and Patient Outcomes) trial, concentrations of hs‐cTnT (high‐sensitivity cardiac troponin T), NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide), hs‐CRP (high‐sensitivity C‐reactive protein), and GDF‐15 (growth differentiation factor 15) were measured in patients with MINOCA at baseline (n=554) and at 1‐month follow‐up (n=107). For comparisons, biomarkers were also measured in patients with MI with obstructive (stenosis ≥50%) coronary artery disease (baseline: n=11 106; follow‐up: n=2755]). Adjusted linear regression models were used to compare concentrations and their short‐ and long‐term changes. The adjusted geometric mean ratios (GMRs) in patients with MINOCA (median age, 61 years; 50.4% women) indicated lower hs‐cTnT (GMR, 0.77 [95% CI, 0.68–0.88]) but higher hs‐CRP (GMR, 1.21 [95% CI, 1.08–1.37]) and GDF‐15 concentrations (GMR, 1.06 [95% CI, 1.02–1.11]) at baseline compared with patients with MI with obstructive coronary artery disease, whereas NT‐proBNP concentrations were similar. Temporal decreases in hs‐cTnT, NT‐proBNP, and hs‐CRP concentrations until 1‐month follow‐up were more pronounced in patients with MINOCA. At follow‐up, patients with MINOCA had lower concentrations of hs‐cTnT (GMR, 0.71 [95% CI, 0.60–0.84]), NT‐proBNP (GMR, 0.45 [95% CI, 0.36–0.56]), and hs‐CRP (GMR, 0.68 [95% CI, 0.53–0.86]). One‐month GDF‐15 concentrations were similar between both groups with MI.Conclusions: Biomarker concentrations suggest greater initial inflammatory activity, similar degree of myocardial dysfunction, and less pronounced myocardial injury during the acute phase of MINOCA compared with MI with obstructive coronary artery disease but also faster myocardial recovery.CLINICAL TRAIL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00391872.
|
|
| 10. |
- Hjort, Marcus, et al.
(författare)
-
Differences in biomarker concentrations and predictions of long-term outcome in patients with ST-elevation and non-ST-elevation myocardial infarction
- 2021
-
Ingår i: Clinical Biochemistry. - : Elsevier BV. - 0009-9120 .- 1873-2933. ; 42, s. 1268-1268
-
Tidskriftsartikel (refereegranskat)abstract
- Background: Differences in biomarkers reflective of pathobiology and prognosis between ST-elevation myocardial infarction (STEMI) and non-ST-elevation myocardial infarction (NSTEMI) are incompletely understood and may offer insights for tailoring of treatment. Methods: This registry-based study included 538 STEMI and 544 NSTEMI patients admitted 2008–2014. Blood samples were collected day 1–3 after admission and 175 biomarkers were analyzed using Proximity Extension Assay and Multiple Reaction Monitoring mass spectrometry. Adjusted Lasso analysis (penalized logistic regression model) was used to select biomarkers that discriminated STEMI from NSTEMI patients. Biomarkers identified by the Lasso analysis were then evaluated in adjusted Cox regressions for associations with death or major adverse cardiovascular events. Results: Biomarkers strongly discriminated STEMI and NSTEMI when considered simultaneously in adjusted Lasso analysis (c-statistic 0.764). Eleven biomarkers independently discriminated STEMI and NSTEMI; seven showing higher concentrations in STEMI: myoglobin, N-terminal pro-B-type natriuretic peptide, serum amyloid A-1 and A-2 protein, ST2 protein, interleukin-6 and chitinase-3-like protein 1; and four showing higher concentrations in NSTEMI: fibroblast growth factor 23, membrane-bound aminopeptidase P, tumor necrosis factor-related activation-induced cytokine and apolipoprotein C-I. During up to 6.6 years of prognostic follow-up, none of these biomarkers exhibited different associations with adverse outcome between STEMI and NSTEMI. Conclusions: In the acute setting, biomarkers indicated greater myocardial dysfunction and inflammation in STEMI, whereas they displayed a more diverse pathophysiologic pattern in NSTEMI patients. These biomarkers were similarly prognostic in STEMI and NSTEMI patients. The results do not support treating STEMI and NSTEMI patients differently based on the concentrations of these biomarkers.
|
|
